Abstract: Disclosed are pharmaceutical compositions comprising a radical scavenging agent and an anti-inflammatory agent which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of a radical scavenging agent, an anti-inflammatory agent, and a sunscreen are also disclosed.Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

Abstract: The subject invention involves processes for making granular compositions comprising soil release polymers, the polymers comprising at least about 10% of substantially linear esters having a backbone; the esters being uncapped or end-capped on one or both ends of the backbone; the esters comprising in their backbones oxyalkyleneoxy units and hydrophobic aryldicarbonyl units; the esters having a molecular weight of from about 500 to about 20,000; the polymers if in solid state having the tendency when exposed to moisture to spontaneously rearrange from an amorphous form which is readily soluble in water to a crystalline form which is relatively insoluble in water; the process comprising the following steps:a) taking the soil release polymers, in which are dispersed from 0% to about 25% alkylaryl or alkyl sulfonate crystallization-reducing stabilizers, in molten state at a temperature of at least about 180.degree. C.

Abstract: The subject invention involves compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo; and(c) R" is selected from hydrogen, methyl, ethyl and i-propyl.The subject invention also involves pharmaceutical compositions containing such novel compounds, compositions thereof and the use of such compounds for preventing or treating respiratory, ocular and/or gastrointestinal disorders.

Abstract: A compound having the structure: ##STR1## wherein (a) W is --C(X')--NRR' or --NR--C(X')R';(b) X and X' are independently O or S;(c) each Y is independently hydrogen or straight, branched or cyclic alkanyl having from 1 to about 3 carbon atoms, or the two Y's are bonded to form an alkanyl ring having from 3 to about 7 carbon atoms;(d) Z is unsubstituted branched or cyclic alkyl, or unsubstituted or alkanyl-substituted phenyl or benzyl, Z having from 3 to about 10 atoms other than hydrogen;(e) R and R' are each independently selected from hydrogen, hydroxy straight, branched or substituted alkyl having from 1 to about 6 carbon atoms, and cyclic alkyl having from 3 to about 7 carbon atoms; unsubstituted or substituted aryl, heteroaryl or heterocyclic groups; or R and R' are bonded together to form a ring having from from 3 to about 8 atoms wherein about 1 to about 4 atoms may be heteroatoms;pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.

Abstract: A compound having the structure: ##STR1## wherein (a) X is oxygen or sulfur;(b) each Y is independently hydrogen or unsubstituted straight, branched or cyclic alkanyl having from 1 to about 3 carbon atoms, or the two Y's are bonded to form an alkanyl ring having from 3 to about 7 carbon atoms;(c) Z is hydrogen or unsubstituted branched or cyclic alkyl, or unsubstituted or alkanyl-substituted phenyl, having from 3 to about 10 atoms other than hydrogen;(d) W is straight, branched or cyclic alkyl or aryl, unsubstituted or substituted, saturated or mono- or di-unsaturated with double bonds except that no terminal carbon atom of W is part of a double bond; W having from 1 to about 15 atoms other than hydrogen; pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.

Abstract: The subject invention relates to compounds having the structure: ##STR1## wherein (a) n is an integer from 1 to about 3;(b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S;(c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and(d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating one or more of respiratory disorders, ocular disorders, and gastrointestinal disorders.

Abstract: A compound having the structure: ##STR1## wherein (a) X is oxygen or sulfur;(b) each Y is independently hydrogen or unsubstituted straight, branched or cyclic alkanyl having from 1 to about 3 carbon atoms,. or the two Y's are bonded to form an alkanyl ring having from 3 to about 7 carbon atoms;(c) Z is hydrogen or unsubstituted branched or cyclic alkyl, or unsubstituted or alkanyl-substituted phenyl, having from 3 to about 10 atoms other than hydrogen;(d) W is straight, branched or cyclic alkyl or aryl, unsubstituted or substituted, saturated or mono- or di-unsaturated with double bonds except that no terminal carbon atom of W is part of a double bond; W having from 1 to about 15 atoms other than hydrogen;pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.

Abstract: The present invention relates to methods and compositions for prevention or treatment of bone loss due to periodontal disease, oral osseous surgery, periodontal flap surgery, tooth extraction, dental implants, or scaling and root planing comprising topical administration, to mucosal tissues of the oral cavity, of a composition having from about 0.001% to about 0.2% ketorolac in the oral cavity.

Abstract: The subject invention relates to low-aqueous gelling compositions comprising optically enriched gellants having the structure: ##STR1## wherein A and B independently represent alkyl groups such that the gellant is an asymmetric, di-chiral, di-hydroxy fatty acid that is about 90% or more in the R, R or S, S form and has from about 6 to about 30 carbon atoms.

Abstract: The subject invention relates to low-aqueous gelling compositions comprising optically enriched gellants having the structure: ##STR1## wherein A and B independently represent alkyl groups such that the gellant is an asymmetric, di-chiral, di-hydroxy fatty acid that is about 90% or more in the R, R or S, S form and has from about 6 to about 30 carbon atoms.

Abstract: The present invention relates to a detergent composition comprising a gel wholly or predominantly in hexagonal liquid crystal phase, said gel comprising:(a) from about 15% to about 50% ethoxylated alkyl sulfate surfactant by weight of the gel, wherein the alkyl group of the ethoxylated alkyl sulfate surfactant has an average from about 8 to about 20 carbon atoms, and wherein the ethoxylated alkyl sulfate surfactant has an average degree of ethoxylation from about 0.5 to about 15;(b) from about 1% to about 20%, by weight of the gel, secondary sulfonate surfactant selected from the group consisting of alkylbenzene sulfonates, alkyltoluene sulfonates, paraffin sulfonates, olefin sulfonates, alpha-sulfonated fatty acid alkyl esters, and mixtures thereof;(c) optionally from 0% to about 15% other surfactants by weight of the gel;(d) from about 40% to about 80% water by weight of the gel;(e) from about 0.

Abstract: Disclosed are novel saponins containing 5-C-hydroxymethylhexose and a sterol or triterpene. These materials, when consumed by humans and animals, lower the cholesterol level in the blood. These compounds can be administered as pharmaceutical preparation to the diet, or incorporated into food compositions.

Abstract: The subject invention relates to methods for sebum control and treatment of acne in mammalian skin and scalp comprising administration of hesperetin, having the structure: ##STR1## or a pharmaceutically-acceptable salt thereof.

Abstract: The subject invention encompasses methods and compositions comprising phosphate derivatives of triclosan for treating or preventing dental plaque, gingivitis or periodontal disease, of the oral cavity in humans or lower animals.

Abstract: A continuous process for producing high active, high density detergent granules consists essentially of the following steps:(a) preparing a mixture in a high-speed mixer, the mixture being prepared from components fed to the mixer consisting essentially of the following:(1) from about 15% to about 35% anionic surfactant acid selected from alkylbenzene sulfonic acid and alkyl sulfuric acid and mixtures thereof;(2) from about 5% to about 65% phosphate builder selected from polyphosphates and pyrophosphates and mixtures thereof; and(3) from about 10% to about 65% particulate carbonate selected from sodium carbonate and potassium carbonate and mixtures thereof, the amount of carbonate being at least about 2 times the amount theoretically needed to neutralize the anionic surfactant acid;(b) agglomerating the mixture from step (a) in a moderate-speed mixer; whereby the anionic surfactant acid is neutralized by the carbonate, and the resulting detergent granules have a bulk density of greater than about 550 g/l and

Abstract: The subject invention involves a method for treating hyperproliferative conditions in mammalian epithelial cells comprising administering to the mammal a composition containing a safe and effective amount of a lysophosphatidic acid compound or derivative having the structure ##STR1## or a cyclic derivative thereof having the structure ##STR2## or a pharmaceutically acceptable salt thereof, wherein: a) --Y-- is --0-- or --CH.sub.2 --;b) --Z is --XH, --H or halo;c) each --X-- is independently --0-- or --S--; andd) --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 11 to about 23 carbon atoms.

Abstract: The subject invention involves compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo; and(c) R' is selected from hydrogen, methyl, ethyl and i-propyl.The subject invention also involves pharmaceutical compositions containing such novel compounds, compositions thereof and the use of such compounds for preventing or treating respiratory, ocular and/or gastrointestinal disorders.

Abstract: A process for preparing a high-density granular detergent product by dry neutralizing alkylbenzene sulfonic acid with a particulate mixture of a water-soluble alkaline inorganic material, for example, sodium carbonate, and a hydratable inorganic detergent builder in an apparatus which provides both mixing and shearing of the particulate mixture, e.g. a V-Blender, thereby forming the granular detergent product. The process includes the addition of particles of pH sensitive detergent surfactant, such as alkyl sulfate, into the particulate mixture prior to the addition of the alkylbenzene sulfonic acid. The high-density product has good product homogeneity and surfactant solubility, and essentially no reversion of the alkyl sulfate to the corresponding fatty alcohol due to acid-catalyzed hydrolysis. Other pH sensitive detergent surfactants include alpha-sulfonated fatty acid alkyl ester and polyhydroxy fatty acid amides.

Abstract: The subject invention relates to methods for regulating wrinkles in mammalian skin comprising topical application of a lysophosphatidic acid compound having the structure: ##STR1## or a cyclic derivative thereof having the structure: ##STR2## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 12 to about 23 carbon atoms; each --X-- is independently --O-- or --S--; and --Y-- is --O-- or --CH.sub.2 --.

Abstract: The subject invention relates to antiperspirant gel compositions comprising chelators. The subject invention also relates to a process for the manufacture of antiperspirant gel compositions comprising the steps of:(a) pre-mixing a chelator with an antiperspirant active in a substantially water free environment; and(b) adding a gelling agent and a liquid base material to the product of step (a) in a substantially water free environment.